The major pathological features of Alzheimer's disease (AD) include amyloid plaques composed primarily of the ␤-amyloid (A␤) peptide, degenerating neurons and neurofibrillary tangles, and the presence of numerous activated astrocytes and microglia. Although extensive genetic data implicate A␤ in the neurodegenerative cascade of AD, the molecular mechanisms underlying its effects on neurons and glia and the relationship between glial activation and neuronal death are not well defined. A␤ has been shown to induce glial activation, and a growing body of evidence suggests that activated glia contribute to neurotoxicity through generation of inf lammatory cytokines and neurotoxic free radicals, such as nitric oxide (NO), potent sources of oxidative stress known to occur in AD. It is therefore crucial to identify specific A␤-induced molecular pathways mediating these responses in activated glia. We report that A␤ stimulates the activation of the transcription factor NFB in rat astrocytes, that NFB activation occurs selectively from p65 transactivation domain 2, and that A␤-induced NO synthase expression and NO production occur through an NFB-dependent mechanism. This demonstration of how A␤ couples an intracellular signal transduction pathway involving NFB to a potentially neurotoxic response provides a key mechanistic link between A␤ and the generation of oxidative damage. Our results also suggest possible molecular targets upon which to focus future drug discovery efforts for AD.
Alzheimer's disease (AD) is a neurodegenerative disorder resulting in progressive neuronal death and memory loss. Neuropathologically, the disease is characterized by neurofibrillary tangles and neuritic plaques composed of aggregates of ␤-amyloid (A␤) protein, a 40-43 amino acid proteolytic fragment derived from the amyloid precursor protein. The importance of A␤ in AD has been shown by means of several transgenic animal studies. The overexpression of mutant amyloid precursor protein results in neuritic plaque formation and synapse loss (1) and correlative memory deficits, as well as behavioral and pathological abnormalities similar to those found in AD (2) .
Neuritic plaques in AD are densely surrounded by reactive astrocytes (3, 4) . These reactive astrocytes participate in the inflammatory response observed in AD by their production of proinflammatory cytokines such as interleukin 1␤ (5) , and by their expression of inducible nitric oxide synthase (iNOS) (6, 7) . iNOS generates nitric oxide (NO) and NO-derived reactive nitrogen species such as peroxynitrite. One possible pathology of AD therefore can be viewed as the accumulation of such free radicals during inflammation resulting in lipid peroxidation, tyrosine nitrosylation, DNA oxidative damage, and ultimately neuronal destruction within the brain (8) (9) (10) (11) . Understanding the expression of iNOS in the AD brain is therefore critical. NOS immunoreactivity has been observed near A␤ neuritic plaques (7) , and iNOS expression can be stimulated in cultured astrocytes or microglia by A␤ (6, (12) (13) (14) (15) . This A␤ stimulation of iNOS can result in the production of excessive amounts of diffusible NO, which when converted to peroxynitrite, becomes a powerfully detrimental oxidant with direct cytopathological consequences (16) .
Relatively little is known about the molecular mechanisms governing A␤ stimulation of astrocyte iNOS activity. One candidate pathway involves the transcription factor NFB (17) . NFB is a heterodimeric transcription factor composed of subunits from the Rel family of proteins. It is located in the cytoplasm as an inactive complex when associated with its inhibitor IB, which masks the NFB nuclear localization signal. Upon stimulation by cytokines or cellular stress, NFB can be rapidly activated by the phosphorylation of IB at serine residues, which direct IB for proteosome-mediated degradation (18) . The activated NFB heterodimer is then free to translocate into the nucleus and bind to specific 10-bp response elements of target genes, typically found in inflammationresponsive genes. The iNOS promoter contains at least one NFB response element (19) , and activated NFB is an important transcription factor in iNOS gene expression in response to cytokines or cellular stress (20) . Recently, NFB was observed immunohistochemically in postmortem AD brain (21) .
We report here that A␤ activates NFB in cultured rat astrocytes and demonstrate that A␤ stimulation of iNOS expression and NO production occurs through an NFBdependent mechanism. These data define a specific molecular pathway that links A␤ activation of glia to a potentially neurotoxic oxidative stress response, and support the concept that A␤-induced oxidative damage is neuropathogenic in AD.
MATERIALS AND METHODS
Cell Culture and Amyloid ␤ 1-42 Peptide (A␤42) Preparation. Cultured rat cortical astrocytes were prepared and tertiary cultures made as described (22) . Cells were maintained in ␣MEM supplemented with 10% fetal bovine serum (FBS) (HyClone) and antibiotics [100 units/ml penicillin͞100 g/ml streptomycin (GIBCO͞BRL)]. Twenty-four hours before stimulation, astrocyte medium was removed, cells were washed once with prewarmed PBS, and then serum-free ␣MEM containing N2 media supplement (GIBCO͞BRL) was added to the cultures. A␤ peptides [A␤ 1-42 or scrambled 1-42 sequence (A␤42scr) KVKGLIDGAHIGDLVYEFMD-SNSAIFREGVGAGHVHVAQVEF] were either purchased (Bachem) or prepared as described previously (6) . A␤ peptides were aggregated as described previously (6) . Briefly, a 20ϫ A␤ peptide stock was subjected to 2-day acidic aging conditions (200 M A␤ in 1 mM HCl) at room temperature, or a 10ϫ A␤ stock was subjected to 1-day neutral aging conditions (100 M A␤ in ␣MEM͞0.2% dimethyl sulfoxide) at 4°C. The aggregated A␤ stocks contained both fibrillar species and globular oligomeric aggregates by atomic force microscopy. The A␤ stocks were then added to the cultures at the appropriate stimulus concentration.
Electrophoretic Mobility-Shift Assays (EMSA). Nuclear extracts from treated astrocytes were prepared by a modified Dignam method (23) . Briefly, treated cells (10 6 cells per 60-mm dish) were scraped into ice-cold PBS supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were pelleted in microfuge tubes and resuspended in 400 l of ice-cold low-salt buffer A (10 mM Hepes, pH 7.9͞1.5 mM MgCl 2 ͞10 mM KCl). After 10 min on ice, 25 l of 10% Nonidet P-40 was added and the samples were vortexed vigorously for 10 sec. Samples were centrifuged (13,000 ϫ g) for 30 sec at 4°C, and the pellet was resuspended in 30 l of ice-cold high-salt buffer C (20 mM Hepes, pH 7.9)͞25% glycerol͞420 mM NaCl͞1.5 mM MgCl 2 ͞0.2 mM EDTA). Resuspended pellets were allowed to rock gently at 4°C for 30 min and then centrifuged at 4°C for 15 min. The supernatant (nuclear extract) was saved and protein concentration was determined by Bradford assay. Before using both buffer A and buffer C, a fresh mixture of inhibitors was added to each at a final concentration of 1 mM PMSF, 1 g͞ml leupeptin A, 1 mM DTT, and 1 mM sodium orthovanadate. Binding reactions were assayed in 20 l volumes by incubating 3 g of nuclear extract with reaction buffer [50 mM Tris⅐HCl, pH 7.5͞5 mM EDTA͞2.5 mM DT T͞250 mM NaCl͞0.25 mg/ml poly(dI⅐dC)⅐poly(dI⅐dC) (Pharmacia)]. For competition, unlabeled specific (identical NFB oligonucleotide shift probe) or nonspecific (AP2 oligonucleotide shift probe) (Promega) probes were allowed to incubate with appropriate samples in 50-fold molar excess for 10-15 min before incubating all samples with 32 P-labeled oligonucleotide shift probes (approximately 50,000-200,000 cpm) at room temperature for 20 min. ''Super-shifting'' was conducted by then incubating the appropriate samples with Rel family antibodies (6 g per sample) for 45 min at room temperature. Supershift polyclonal antibodies against synthetic peptides from the NFB͞Rel family of proteins p65(RelA), p50, p52, c-Rel(p75), and RelB(p68) were purchased from Santa Cruz Biotechnology. Products were subjected to electrophoresis at 200 V in a 4°C room for approximately 90 min on 5.5% nondenaturing polyacrylamide gels in high ionic strength TGE buffer (50 mM Tris⅐HCl͞380 mM glycine͞2 mM EDTA, pH Ϸ8.5). Lanes with samples were devoid of any loading dyes, which interfere with the binding reactions. Dried gels were exposed to Storm Phosphor Imaging plates (Molecular Dynamics) and viewed by IMAGEQUANT software (Molecular Dynamics). To size EMSA figures to page, the vertical aspect ratio of each picture was reduced by approximately 50%. Oligonucleotides representing the NFB response element (consensus sequence, 5Ј-AGT TGA GGG GAC TTT CCC AGG C-3Ј) were purchased from Promega. Mutant NFB (NFBmut) response element oligonucleotides (5Ј-AGT TGA GGC* GAC TTT CCC AGG C-3Ј, where ‫ء‬ denotes mutated base) were purchased from Santa Cruz Biotechnology. To prepare gel shift probes, oligonucleotides were labeled with [␥-32 P]ATP (Amersham) by using T4 polynucleotide kinase by the protocol provided (gel shift assay system, Promega). Unincorporated nucleotides were removed by Centri-Sep spin columns (Princeton Separations).
Plasmids. 3xRel-LUC was a gift from M. L. Scott and D. Baltimore (Massachusetts Institute of Technology) and contains three tandem Ig B repeats from the construct Ϫ55 to ϩ19 hIFN␤-CAT (24), which were cloned into the NotIHindIII site of pBL, and thereby linked to the luciferase reporter gene. CMV-IB(Super-repressor) [CMV-IB(Sr)] was generously provided by Dean Ballard (Howard Hughes Medical Institute, Vanderbilt University Medical Center). IB was cloned into the expression vector pCMV-4, and serine residues 32 and 36 (sites of phosphorylation that precede IB degradation) have been mutated to alanines (25) . pXP2 backbone vector and 7kb(wt) iNOS-LUC were kindly provided by David Geller (University of Pittsburgh) and have been described (26) . PCR site-directed mutagenesis (QuikChange, Stratagene) was used to mutate the NFB response element immediately upstream of the TATAA box of the 7kb(wt) iNOS-LUC promoter construct (GGG to CTC) to generate the 7kb(NFB Ϫ ) iNOS-LUC promoter construct. DNA sequence analysis confirmed the mutation in the response element and verified the absence of any additional mutations. UAS(5x)-E1B-TATA-LUC (UAS-LUC) contains five tandem repeats of the Gal4 upstream activating sequence cloned pA3-LUC and has been described (27) .
Transient Transfections. Astrocytes were transfected by using the synthetic cationic lipid Tfx-50 (Promega) or by SuperFect transfection reagent (Qiagen, Chatsworth, CA). cells per well for 12-well plates, 1 ϫ 10 4 cells per well for 48-well plates). Cells were immediately exposed to DNA transfecting complexes for 1-2 hr at 37°C. Transfecting complexes were then removed, cells washed once with warm PBS, and incubated for 4-6 hr in ␣MEM (with 20% FBS). This medium was then replaced with ␣MEM containing 10% FBS, and cells were incubated overnight before changing the medium to serumfree N2-supplemented ␣MEM for 24 hr before stimulation. For luciferase assays after the appropriate stimulus, cells were rinsed once with ice-cold PBS and immediately lysed for 5 min at 4°C in lysis buffer (0.5 M Hepes, pH 7.4͞5% Triton N-101͞1 mM CaCl 2 ͞1 mM MgCl 2 ). Lysates were transferred to 96-well black-walled plates (Corning Costar), and an equal volume of reconstituted LucLite luciferase substrate (Packard) was added to each sample. Luciferase reactions were allowed to proceed for approximately 5 min at room temperature before quantitating relative light unit (RLU) output on a LumiCount (Packard) high-throughput luminometer (20-sec reads per sample well). Blank transfections (unstimulated astrocytes transfected with the appropriate backbone vector) were included for each experiment to determine machine noise background, which was then subtracted before data analysis. Each set of data represents results from 6-11 experiments.
Nitrite Assays. Nitrite production by astrocytes was measured by Griess assay as a read-out for iNOS activity as described previously (22) . Astrocytes were treated with various stimuli in a total volume of 100 l per well in a 48-well plate, and 80 l of conditioned medium was collected after 48 hr of stimulus. To measure total nitrite produced in a 48-hr period, any nitrate in the conditioned medium was first reduced back to nitrite with nitrate reductase and NAPDH (Sigma) at 37°C for 1 hr. An equal volume of Griess reagent [0.5% sulfanilamide and 0.05% N-(1-naphthyl) ethylenediamine] was then added to the conditioned medium and the reaction was allowed to proceed for 5 min at room temperature before the absorbance at 540 nm was measured. A sodium nitrite linear range standard curve from 0 to 75 M nitrite was used to determine the concentration of nitrite in the astrocyte conditioned medium.
RESULTS
To characterize the activation state of NFB in astrocytes stimulated by A␤42, we performed EMSA assays on isolated nuclear extracts incubated with 32 P-labeled oligonucleotide probes containing the 10-bp consensus sequence of the NFB response element.
Four mobility-shifted complexes were observed using nuclear extracts from astrocytes treated with A␤42 (Fig. 1, lanes  3, 4, and 5, bands A-D) . Bands A, B, and C exhibited a dose-dependent increase in binding, beginning with nuclear extracts from cells treated with 1 M A␤42 (Fig. 1, lane 3) . In contrast, nuclear extracts from cells treated with a scrambled A␤42 peptide sequence (A␤42scr) exhibited only a modest gel shift at double the maximum concentration of A␤42 (Fig. 1,  lane 7) . The specificity of the NFB response was characterized further by EMSA. Compared with controls (Fig. 2, lanes 1 and  2) , NFB was strongly activated in astrocytes stimulated by A␤42 (Fig. 2, lane 3) . Maximal enhancement of binding was observed by 12 hr after A␤ activation (data not shown). All four bands could be competed away by specific competitor probe (50-fold molar excess of cold cognate competitor; Fig.  2 , lane 5) but not by nonspecific probe (50-fold molar excess of unlabeled oligo shift probe containing the AP2 binding site; Fig. 2, lane 4) . In addition, a mutant oligonucleotide probe that included a 1-bp substitution in the NFB response element sequence exhibited little if any gel shift activity (Fig. 2, lane 6) . Lysates from A␤-activated astrocytes assayed by Western immunoblotting revealed the presence of all five protein members of the Rel family (data not shown). ''Super-shifts,'' conducted with a panel of antibodies specific for each Rel family member, identified p65͞RelA and p50 within the complex (Fig. 2, lanes 7-11) . Bands A, B, and C were shifted by the antibodies to p65͞RelA and p50, but not by the antibodies to p52, c-Rel͞p75, or RelB͞p68. Band D was unaffected by any of these Rel family antibodies.
The activation of NFB was also determined by using the luciferase NFB reporter construct 3xRel-LUC. This reporter construct has three tandem NFB response element repeats upstream of a minimal promoter driving the luciferase gene.
A␤42 treatment induced 3xRel-LUC approximately 4.5-fold over the levels in untreated or vehicle-treated cells (Fig. 3A) . A␤42scr did not stimulate 3xRel-LUC reporter expression levels above untreated or vehicle-treated cells (Fig. 3A) . 3xRel-LUC reporter specificity for NFB was verified by cotransfection with CMV-IB(Sr), an IB ''super-repressor'' expression construct. In this construct, IB serines 32 and 36 have been mutated to alanines, preventing the protein from being phosphorylated, thereby blocking its degradation and thus strongly maintaining inhibition of NFB activity. Overexpression of IB(Sr) blocked A␤42-dependent 3xRel-LUC activity to levels equivalent to unstimulated cells (Fig. 3B) .
Because p65͞RelA was a participating subunit of NFB, a subunit known to have at least two different transactivating domains (TADs) (28), we used two p65 TADs in yeast Gal4-dependent reporter constructs to determine which domain(s) specifically participated in A␤42-stimulated NFB activation. NFB(1)-Gal4 included TAD1 of p65, which contains amino acid residues 520-590, and NFB(2)-Gal4 included TAD2 of p65, which contains amino acid residues 286-518 (29) . Either construct was cotransfected with a luciferase reporter construct containing five tandem repeats of the yeast Gal4-UAS binding site. As shown in Fig. 4 , A␤42 stimulated NFB(2)-Gal4 2-to 3-fold, whereas cells transfected with NFkB(1)-Gal4 showed no induction. In addition, transfected cells treated with A␤42scr showed no significant activity from either TAD1 or TAD2 of p65. Therefore, NFB activation by A␤42 is selectively regulated at the amino acid region of p65͞RelA TAD 2.
We have previously shown that A␤42 can enhance iNOS mRNA expression and nitrite production in cultured astrocytes (6) . To characterize the potential importance of A␤-activated NFB for iNOS activity, we used several approaches. Astrocytes transfected with a human 7-kb iNOS promoter-luciferase construct [7kb(wt) iNOS-LUC] exhibited an approximate 7-to 10-fold increase in luciferase activity in A␤42-activated astrocytes compared with vehicletreated or untreated astrocytes (Fig. 5A Left) . This A␤-induced increase in iNOS promoter activity was almost completely abolished upon mutation of the proximal NFkB response element (5Ј-GGGACACTCC-3Ј to 5Ј-CTCA-CACTCC 3Ј) (Fig. 5A Right) . However, despite a reduction in basal level activity, the 7kb(NFB Ϫ ) iNOS-LUC promoter construct responds to stimulation by 1 mM dibutyryl cAMP in a fashion indistinguishable to that of the 7kb(wt) iNOS-LUC construct (data not shown), demonstrating that NFBindependent signaling pathways were unaffected by mutation of the NFB binding site. Furthermore, cotransfection with CMV-IB(Sr) abrogated A␤-stimulated luciferase activity of the 7-kb iNOS-LUC promoter construct (Fig. 5B (1998) and NO production, as measured by the stable metabolites nitrite and nitrate (Fig. 5C ). These three approaches demonstrate that A␤42 stimulation of iNOS expression and NO production is NFB-dependent.
DISCUSSION
We report here that the neurotoxic 42-aa A␤ peptide stimulates the activation of the transcription factor NFB in cultured rat astrocytes in a dose-dependent manner, whereas a scrambled-sequence A␤42 peptide at an equal concentration does not. Although expression of all five NFB͞Rel proteins can be detected in astrocytes, only specific Rel family members (p50 and p65͞RelA) participate in A␤ activation. Moreover, A␤42 stimulation of NFB occurs selectively from TAD 2 of p65͞ RelA and not from TAD 1. Last, A␤42 stimulation of iNOS gene expression and NO production is almost completely NFB dependent. Nitrogen species such as NO and NO-derived peroxynitrite are strong inducers of oxidative stress. It is therefore important to understand the molecular mechanisms underlying NO activation in an attempt to slow or prevent oxidative injury to the brain. This is emphasized by initial studies on dementia onset and the use of anti-inflammatory drugs and antioxidants (30) (31) (32) . Chronic antioxidant usage, which may curb oxidative damage to cells, appears to result in a delay of dementia in AD patients. A prominent source of the oxidative damage seen in AD is peroxynitrite (16) . Our results are consistent with previous studies that have shown that iNOS expression and peroxynitrite damage occur throughout the AD brain (8) , and that NFB activation can be observed in AD brain sections (21) . However, our data couple A␤42-stimulated NFB activation in AD to the production of iNOS and NO. These studies provide direct support for the postulation (33) of a neurotoxic role for NFB in AD in the context of glia and suggest that in AD, NFB is not ''protective'' in glia as it can be in neurons (34) . These studies also provide a model for how glia participate in the oxidative damage widely seen in AD and allow a focus on specific signaling pathways involving p65͞RelA. A␤42 exposure likely influences multiple signal transduction pathways, some of which ultimately can lead to enhanced NO production and subsequent oxidative damage. It should also be noted that other A␤42-stimulated signal transduction pathways not involving NFB or NO may lead to oxidative injury. Nevertheless, our data, which strongly implicate TAD 2 of NFB p65͞RelA in the induction of NO production by A␤42 and therefore potential oxidative injury to the brain, may provide new therapeutic approaches to AD.
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